Fig. 1: Lung fibroblast-derived EVs and SFs support alveolar organoid formation.
From: Fibroblast-derived osteoglycin promotes epithelial cell repair
a Schematic of in vitro murine organoid design treated with EVs or SFs. b Brightfield images of murine lung organoids on day 14 (scale = 700 µm). c CFE of murine organoids (mean ± SEM, N = 6, one-way ANOVA, Dunnett test). d Log of murine organoid diameter (median, N = 6, Kolmogorov-Smirnov test, α = 0.0025). e Immunohistochemistry quantification for SPC in murine organoids (mean ± SEM, N = 6, one-way ANOVA, Dunnett test). f Schematic of in vitro CSE-exposed murine organoid design. g CFE of CSE-exposed murine organoids (mean ± SEM, N = 8, one-way ANOVA, Dunnett test). h Log of CSE-exposed murine organoid diameter (median, N = 8, Kolmogorov-Smirnov test, α = 0.0167). i Immunofluorescence images of organoids for airway-type (ACT, red), alveolar-type (SPC, green), and DAPI (nuclei, blue) (scale = 500 µm). j Immunohistochemistry quantification for SPC+, ACT+, SPC+/ACT+, and SPC-/ACT- organoids (mean ± SEM, N = 6, one-way ANOVA, Dunnett test). k Schematic of in vitro human organoid design. l CFE of human organoids (mean ± SEM, N = 6, one-way ANOVA, Dunnett test). m Log of human organoid diameter (median, N = 6, Kolmogorov-Smirnov test, α = 0.025). Statistically significant comparisons: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
